Physician profile
Ashwin R Patel
NPI 1811984255
$2,282.19
in general payments reported to CMS, 2019-2025
27 companies · $660 in 2025
The $660 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $128 · 2021: $54.43 · 2022: $188 · 2023: $486 · 2024: $503 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540 · Gift: $59.40 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,540.00 |
| Gift | $59.40 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $708.91 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $184.79 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Mannkind Corporation | $170.48 | 2023-2024 | Afrezza |
| Amgen INC. | $156.31 | 2020-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $101.58 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.48 | 2024-2025 | Jardiance |
| Intuitive Surgical, INC. | $94.57 | 2022 | |
| Pfizer INC. | $84.77 | 2020-2023 | |
| Currax Pharmaceuticals LLC | $81.71 | 2023-2024 | Nexletol, Contrave, Onzetra Xsail |
| Abbott Laboratories | $68.44 | 2023-2025 | Proclaim, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $63.39 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $51.86 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $47.50 | 2022-2023 | Xarelto |
| Novo Nordisk INC | $46.83 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $36.51 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $34.20 | 2019-2020 | |
| Esperion Therapeutics, INC. | $32.26 | 2025 | Nexletol |
| Boston Scientific Corporation | $29.43 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.96 | 2024 | Lifevest |
| Corcept Therapeutics | $25.36 | 2023 | Korlym |
| Phadia US INC. | $24.31 | 2024 | Immunocap |
| Exact Sciences Corporation | $22.50 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $20.16 | 2023 | |
| Aimmune Therapeutics, INC. | $19.07 | 2025 | Zenpep |
| Glaxosmithkline, LLC. | $17.97 | 2023 | Shingrix |
| Qiagen, LLC | $16.86 | 2022 | |
| Allergan, INC. | $14.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.